Dr. Cohen on Biomarkers Associated With Response in Patients With HNSCC Treated With Afatinib
February 18th 2016
Ezra Cohen, MD, associate director, Moores Cancer Center,
professor of Medicine, University of California, San Diego Health System, discusses tumor biomarker association with clinical outcomes in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with afatinib versus methotrexate.